Home/Pipeline/BNC101 (via Carina Biotech)

BNC101 (via Carina Biotech)

Solid Tumors

Out-licensedPartnered

Key Facts

Indication

Solid Tumors

Phase

Out-licensed

Status

Partnered

Company

Neuphoria Therapeutics

About Neuphoria Therapeutics

Neuphoria Therapeutics is dedicated to developing transformative treatments for neuropsychiatric disorders, with a core focus on its lead clinical candidate, BNC210. The company has achieved key milestones, including positive Phase 2b results in PTSD and strategic partnerships with Merck and Carina Biotech, validating its platform. Its strategy centers on advancing BNC210 through late-stage trials for PTSD and broader anxiety indications while leveraging its ion channel targeting expertise to build a pipeline of next-generation CNS therapies.

View full company profile

Therapeutic Areas

Psychiatry Neurology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed
Undisclosed Whole Cell Vaccine Program(s)	Neuvogen	Pre-clinical	Active
SY-5609	Syros Pharmaceuticals	Phase 1/2	Discontinued
Not Specified (TCR Therapy)	T-Cure Bioscience	Phase 1	Active
B7-H3 Program	Ocean Biomedical	Discovery	Active